Overview of ESR1 Mutations in ER+/HER2- Metastatic Breast Cancer

A follow-up of the ShortHER trial suggests tumor-infiltrating lymphocytes (TILs) can help identify patients who may benefit from shorter trastuzumab and chemotherapy regimens.

On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.

Breast cancer screening rates shifted after the 2009 US Preventive Services Task Force (USPSTF) guidelines, with disparities emerging across race, income, and lifestyle factors.

On this episode of Managed Care Cast, we discuss how already wide health care inequities in cancer are becoming much worse because of the COVID-19 pandemic, with guest Monica Soni, MD, associate chief medical officer at New Century Health.

Atezolizumab (Tecentriq) plus chemotherapy after surgery did not improve survival in high-risk triple-negative breast cancer, according to a global phase 3 trial.

The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.